US10814002 — Patch and method for producing the same
Method of Use · Assigned to Hisamitsu Pharmaceutical Co Inc · Expires 2033-07-25 · 7y remaining
What this patent protects
This patent protects a method for producing a patch that includes a specific adhesive layer containing asenapine and sodium diacetate.
USPTO Abstract
A method for producing a patch including a support layer, and an adhesive agent layer formed on the support layer and including sodium diacetate, a pressure-sensitive adhesive base agent, and asenapine and/or a pharmaceutically acceptable salt thereof. The sodium diacetate is generated from sodium acetate in the presence of the asenapine and/or salt thereof, a content of the asenapine and/or salt thereof in terms of free asenapine in the adhesive agent layer is in range of 3.0 to 20 mg, and when a content of the asenapine and/or salt thereof in terms of free asenapine in the adhesive agent layer is 6.4 mg and the patch is in contact with skin for 24 hours, C max of free asenapine is in range of 0.5 to 6.0 ng/mL and t max of free asenapine is in range of 8 to 28 hr.
Drugs covered by this patent
- Saphris (ASENAPINE) · Hisamitsu
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2763 |
— | Saphris |
U-2763 |
— | Saphris |
U-2763 |
— | Saphris |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.